4P Pharma, Translating Science to Medicine for Patients
Established in 2014, 4P-Pharma is a clinical stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients …
Discover 4P-Pharma’s clinical vision
Dec 14, 2022 · 4P-Pharma has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk …
Pipeline - 4P Pharma
4P-Pharma pipeline covers an extensive spectrum of therapeutic areas, encompassing chronic and autoimmune diseases, respiratory and infectious diseases, preventive therapies, and …
4P-Pharma Reveals Its Brand New Identity
Apr 23, 2024 · 4P-Pharma Reveals Its Brand New Identity This new identity represents a significant milestone in our company’s journey, from a biotech start-up to a clinical-stage biotech dedicated to …
Legal Mention - 4P Pharma
Any reproduction, even partial, of any content of our website is strictly prohibited without the express authorization of 4P-Pharma. The logo and domain name “www.4p-pharma.com” are protected …
Discover our second video focus on our preclinical department - 4P …
Dec 1, 2022 · 4P-Pharma is pleased to share the second video of a series of three videos made in collaboration with Entreprendre magazine in order to highlight innovative biotechnology companies.
4P-Pharma at the 3rd International Symposium Research on Healthy …
Dec 4, 2019 · A poster on 4P-004 entitled “Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies” will be presented during the 3rd International Symposium …
4P-Pharma supports World Rare Disease Day
Feb 29, 2024 · 4P-Pharma supports World Rare Disease Day On World Rare Disease Day, our team stands together to show support for those who suffer from rare diseases. For the past ten years, our …
4Moving Biotech forms its Scientific Advisory Board of World …
Nov 10, 2023 · 4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate’s phase 2b clinical trial.
4P-Pharma Announces Total Capital of €15 Million Successfully …
Apr 29, 2024 · With this funding, 4P-pharma’s shareholders renew their confidence in the company’s drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical …